Last reviewed: July 8, 2026
Last updated: July 8, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide (Wegovy) and tirzepatide (Mounjaro) represent two distinct classes of weight loss medications approved by the FDA, each targeting different hormone pathways in the body. While both medications help people lose weight, they operate through separate mechanisms and produce different clinical outcomes. Understanding how each works can help you make an informed decision about your weight loss journey.
How Semaglutide and Tirzepatide Work Differently
Semaglutide, marketed as Wegovy for weight loss, mimics a single hormone called glucagon-like peptide-1 (GLP-1). This hormone tells your brain you are full, slows your stomach emptying, and helps regulate blood sugar. By activating GLP-1 receptors throughout your body, semaglutide creates a powerful satiety signal that reduces hunger and food intake.
Tirzepatide, sold as Mounjaro, activates both GLP-1 and another hormone pathway called GIP (glucose-dependent insulinotropic polypeptide). This dual-receptor activation means tirzepatide hits two separate hunger and metabolism control centers at once. The added GIP activation provides an extra layer of appetite suppression and may enhance insulin sensitivity beyond what single-pathway therapy achieves.
Clinical Weight Loss Results: Head-to-Head Evidence
In the STEP trial, semaglutide users lost an average of 15% of their body weight over 68 weeks at the highest dose. This represented a substantial improvement over placebo and established semaglutide as a major breakthrough in weight management. The medication proved effective across diverse patient populations with varying starting weights.
The SURMOUNT trials showed tirzepatide produced weight loss ranging from 16% to 22% depending on the dose used. At the highest tirzepatide dose, participants lost approximately one pound more per week on average than those on the highest semaglutide dose. For someone starting at 250 pounds, this difference could mean 10 to 20 additional pounds lost over a treatment year.
The superior tirzepatide results likely stem from its dual GIP/GLP-1 activation, which engages more metabolic pathways simultaneously. However, individual responses vary significantly based on genetic factors, baseline metabolism, and lifestyle choices. Some patients achieve their goals with semaglutide alone, while others benefit from tirzepatide's stronger dual action.
Side Effects and Tolerability Differences
Both medications commonly cause nausea, vomiting, diarrhea, and constipation, particularly during dose escalation. Semaglutide users report these gastrointestinal effects in roughly 40% of cases, most often mild to moderate and temporary. The side effect profile of semaglutide has been well-studied across millions of patients globally.
Tirzepatide causes similar gastrointestinal symptoms but at somewhat higher rates due to its dual-pathway activation. Approximately 25% of tirzepatide users experience nausea or vomiting, though severe cases requiring treatment discontinuation remain uncommon. Both medications show that side effects typically decrease after the first 2-4 weeks as your body adapts to the medication.
The PlexusDx Precision Peptide Genetic Test analyzes GLP1R, GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to Mounjaro or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.
Cost Comparison and Access to Compounded Options
Wegovy and Mounjaro carry significant out-of-pocket costs when purchased through traditional pharmacies, often exceeding $900 to $1,400 per month without insurance coverage. Many insurance plans deny coverage or require prior authorization, leaving patients to pay full retail prices. The branded pharmaceutical route creates financial barriers for millions of people who would benefit from these medications.
PlexusDx compounded tirzepatide injection starts at $289/mo (or $249/mo on the 6-month plan) from licensed 503A compounding pharmacies, representing a 70-80% reduction from brand-name Mounjaro pricing. Compounded semaglutide injection begins at $189/mo (or $149/mo on the 6-month plan), making both pathways accessible without insurance. Your dose may need to go up over time for continued weight loss, but your price won't—the same monthly rate applies regardless of dose level.
PlexusDx serves all 50 states with no membership fees or insurance requirements. HSA and FSA accounts are accepted, providing additional savings pathways. This approach brings prescription weight loss medication within reach for people priced out of the brand-name market.
Choosing Between Wegovy, Mounjaro, or Compounded Alternatives
The choice between semaglutide and tirzepatide depends on your specific health history, weight loss goals, genetic predispositions, and budget. Tirzepatide's superior weight loss results make it ideal for patients needing maximum fat loss, while semaglutide suits those prioritizing gentler side effect profiles or who have responded well to GLP-1 therapy before. Neither medication works equally well for everyone—personalization matters.
PlexusDx offers both compounded semaglutide and tirzepatide injections, plus dual-compound GLP-Squared formulations that combine both pathways. The Precision Peptide Genetic Test identifies your GLP1R, GIPR, FTO, and MC4R variants, revealing which peptide pathways your body responds to most effectively. This genetic insight removes guesswork and helps match you with the medication most likely to deliver results.
Your weight loss success depends more on consistency, nutrition, movement, and stress management than on choosing between these two medications. Either semaglutide or tirzepatide, when paired with lifestyle changes, can help you reach meaningful weight loss milestones. PlexusDx makes both options affordable and accessible without sacrificing quality or safety.
How Your Genetics Relate to GLP-1 Pathways
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $289/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Which is better for weight loss: Wegovy or Mounjaro?
Mounjaro (tirzepatide) produces approximately 5-7% greater weight loss than Wegovy (semaglutide) based on clinical trials, primarily because it activates two hormone pathways instead of one. However, individual results vary significantly, and some patients achieve excellent outcomes with semaglutide. The 'better' choice depends on your genetics, medical history, side effect tolerance, and weight loss goals.
Can I switch from Wegovy to Mounjaro if it's not working?
Yes, many patients switch from semaglutide to tirzepatide if they plateau or need stronger appetite suppression. Your PlexusDx provider can help evaluate whether a medication switch or dose adjustment makes sense based on your progress and tolerance. The transition typically involves a gradual transition period to minimize side effects.
How much does Mounjaro cost compared to compounded tirzepatide at PlexusDx?
Brand Mounjaro costs $900-$1,400+ monthly without insurance, while PlexusDx compounded tirzepatide injection starts at $289/mo (or $249/mo on the 6-month plan) from licensed 503A pharmacies. This represents approximately 70-80% savings with the same active medication ingredient and quality standards, with no membership fees or insurance required.
Are compounded medications as safe and effective as brand-name Wegovy and Mounjaro?
PlexusDx compounds semaglutide and tirzepatide through licensed 503A compounding pharmacies, which follow strict FDA regulations and quality standards identical to brand-name production. The active ingredients are identical; compounding simply bypasses the branded pharmaceutical markup while maintaining full safety and efficacy.
How does the Precision Peptide Genetic Test help me choose between semaglutide and tirzepatide?
No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GLP1R, GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.
Related Reading
Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Navigating the Ozempic Journey for Weight Loss Success
Which One is Better for Weight Loss: Ozempic or Mounjaro?